---
document_datetime: 2025-09-09 15:56:40
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ecalta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ecalta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.427294
conversion_datetime: 2025-12-20 10:12:06.865274
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ECALTA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 09/09/2025                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282338   |
|---------------------|

<div style=\"page-break-after: always\"></div>

| changes by introducing the full term 'invasive candidiasis including candidaemia' before the abbreviation 'ICC' in Section 4.8 of the SmPC, retaining only the abbreviation in Section 5.1, updating the local representative information for IE in the PL, and removing the representative for the United Kingdom (Northern Ireland) in line with the QRD template. C.I.z (Type IA) - To update Section 5.1 of the EU SmPC to include a weblink to the European Medicines Agency (EMA) referencing susceptibility testing breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for anidulafungin.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|